Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 14, 2013; 19(34): 5622-5632
Published online Sep 14, 2013. doi: 10.3748/wjg.v19.i34.5622
Published online Sep 14, 2013. doi: 10.3748/wjg.v19.i34.5622
Figure 3 Recurrence-free survival probabilities according to the following.
A: Pre-transplant treatment type (log-rank P = 0.0493); B: Adherence to Milan Criteria at pathology (log-rank P < 0.0001); C: Percentage of necrosis in the cumulative tumor area (log-rank P = 0.0098); D: Pre-transplant serum α-fetoprotein level (log-rank P = 0.0008). TACE: Transcatheter arterial chemoembolization; DEB: Doxorubicin-eluting bead; LT: Liver transplantation; CTA: Cumulative tumor area; c-TACE: Conventional TACE.
-
Citation: Nicolini D, Svegliati-Baroni G, Candelari R, Mincarelli C, Mandolesi A, Bearzi I, Mocchegiani F, Vecchi A, Montalti R, Benedetti A, Risaliti A, Vivarelli M. Doxorubicin-eluting bead
vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation. World J Gastroenterol 2013; 19(34): 5622-5632 - URL: https://www.wjgnet.com/1007-9327/full/v19/i34/5622.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i34.5622